{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:24Z","timestamp":1747181124550,"version":"3.40.5"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Wellens syndrome is a comprehensive electrocardiographic (ECG) diagnosis that combines medical history with characteristic ECG changes. These changes, characterized by biphasic T-wave inversions or symmetric and deep T-wave inversions in the anterior precordial leads, often indicate that the left anterior descending coronary artery is at a high risk of severe stenosis. Chemotherapy-related cardiovascular toxicity refers to damage to the cardiovascular system caused by chemotherapeutic drugs, which is unpredictable and may occur during or after chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>In this case report, a 41-year-old male patient with cholangiocarcinoma received sequential adjuvant chemotherapy with gemcitabine\/nanoparticle albumin\u2013bound paclitaxel and gemcitabine\/cisplatin. This patient presented with recurrent brief chest pain episodes after the third dose of gemcitabine\/cisplatin, and the characteristic T-wave morphological changes were captured in routine ECG monitoring prior to the 6th dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Acute coronary syndrome due to chemotherapy-related cardiovascular toxicity was diagnosed on the basis of characteristic ECG changes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient underwent coronary angiography, which revealed diffuse stenosis of up to 95% in the middle segment of the left anterior descending coronary artery. Stents were implanted in the stenotic segment for vascular reconstruction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient\u2019s chest pain was completely resolved, and electrocardiography returned to normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Cardiovascular toxicity during chemotherapy in patients with cancer may be life threatening. This rare case highlights the importance of identifying the characteristic ECG pattern of the Wellens syndrome by monitoring electrocardiography during chemotherapy. Immediate and accurate identification of the morphological ECG features of Wellens syndrome with a slight elevation of the ST-segment is related to patient prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033599","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T14:03:54Z","timestamp":1682690634000},"page":"e33599","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Wellens syndrome during chemotherapy for cholangiocarcinoma: A case report of cardiovascular toxicity associated with gemcitabine-containing regimen"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1310-6049","authenticated-orcid":false,"given":"Xufei","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Function, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhong","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Function, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Function, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Function, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Function, Fourth Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies.","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"issue":"4 Pt 2","key":"R4-20250504","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0002-8703(82)90480-X","article-title":"Characteristic electrocardiographic pattern indicating a critical stenosis high in left anterior descending coronary artery in patients admitted because of impending myocardial infarction.","volume":"103","author":"de Zwaan","year":"1982","journal-title":"Am Heart J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9149(83)90061-9","article-title":"Anatomic and prognostic significance of new T-wave inversion in unstable angina.","volume":"52","author":"Haines","year":"1983","journal-title":"Am J Cardiol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/ajem.2002.34800","article-title":"Electrocardiographic manifestations of Wellens\u2019 syndrome.","volume":"20","author":"Rhinehardt","year":"2002","journal-title":"Am J Emerg Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/emermed-2017-206665.1","article-title":"Bet 1: in patients with suspected acute coronary syndrome, does Wellens\u2019 sign on the electrocardio graph identify critical left anterior descending artery stenosis?","volume":"34","author":"Morris","year":"2017","journal-title":"Emerg Med J"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jamainternmed.2019.0216","article-title":"A nearly stressful situation\u2013a case of Wellens syndrome.","volume":"179","author":"Yazdi","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0196-0644(99)70373-2","article-title":"Wellens\u2019 syndrome.","volume":"33","author":"Tandy","year":"1999","journal-title":"Ann Emerg Med March"},{"key":"R10-20250504","first-page":"1316","article-title":"Delayed therapy for Wellens\u2019syndrome resulted in acute myocardial infarction.","volume":"70","author":"Canpolat","year":"2012","journal-title":"Kardiol Pol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14740\/jmc3417","article-title":"Gemcitabine-related acute coronary syndrome.","volume":"11","author":"Hazam","year":"2020","journal-title":"J Med Cases"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/ph13100325","article-title":"Cardiotoxicity associated with gemcitabine:literature review and a pharmacovigilance study.","volume":"13","author":"Hilmi","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl. S5","key":"R14-20250504","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine.","volume":"17","author":"Mini","year":"2006","journal-title":"Ann Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ehf2.12113","article-title":"Gemcitabine induced cardiomyopathy: a case of multiple hit cardiotoxicity.","volume":"4","author":"Mohebali","year":"2017","journal-title":"ESC Heart Fail"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"R17-20250504","first-page":"117","article-title":"A reassessment of cardiac toxicity associated with taxol.","volume":"(15)","author":"Arbuck","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects.","volume":"3","author":"Florea","year":"2011","journal-title":"Cancers (Basel)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:00:44Z","timestamp":1746324044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":19,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033599","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}